All Research on Biotech

Insight

Case Studies
Case Studies

Alexion Pharmaceuticals, Inc.: Focus on ultra-rare diseases as a revenue and profit driver

In 2007, Alexion gained marketing approval for Soliris, which has since become the world’s single most expensive orphan drug. This case study analyzes Alexion's success with Soliris, potential challenges, and how it is combatting these going forward.

Published By MarketLine
$495
Buy
Report
Report

The Orphan Drug Market Outlook to 2017

This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.

Published By Datamonitor
$2800
Buy
Report
Report

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality

Datamonitor provides an overview of and profiles key hemophilia A and B pipeline products launching in the near future in the US and five major EU markets (France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
$2800
Buy

View all Insight >>

Market Data

Databook
Databook

Company Financials: Sunesis Pharmaceuticals, Inc.

In-depth Company Financials with Key Ratios, and Revenue details by segments and geographies for the last five years download the attached datapack (.xls file)

Published By Datamonitor
$75
Buy

Profiles

Company Profile
Company Profile

Cubist Pharmaceuticals, Inc.

Cubist Pharmaceuticals (Cubist or 'the company') is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company operates primarily in the US. Cubist is headquartered in Lexington, Massachusetts, and employed 873 people as of February 01, 2014.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

Amgen, Inc.

Amgen (or 'the company') is a leading biotechnology company engaged in the discovery, development, manufacture, and marketing of innovative human therapeutics. The company mainly focuses in the areas of cancer, kidney disease, rheumatoid arthritis and other serious illnesses. It primarily operates in the US where it is headquartered in Thousand Oaks, California. Amgen employed about 20,000 people as of December 31, 2013.

Published By MarketLine
$175
Buy
Company Profile
Company Profile

Biogen Idec, Inc.

Biogen Idec (Biogen or 'the company') is a biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of therapies in the areas of oncology, neurology and immunology. The company's key products include Tysabri (natalizumab), Avonex (Interferon beta-1a) and Rituxan (rituximab). The company primarily operates in the US and Europe. It is headquartered in Weston, Massachusetts and employed about 6,850 people as of December 31, 2013.

Published By MarketLine
$175
Buy

View all Profiles >>

No help is available.